Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Medesis Pharma S.A., a clinical development stage biopharmaceutical company, engages in the development of orally administered molecule drug candidates to address unmet medical needs. Its products include NanoLithium (NP03), a clinical stage development product for the treatment of Alzheimer's disease; NanosiRNA DH for the treatment of Huntington's Disease; NU01 Plutonium and NU02 Cesium decorporation products for nuclear decorporation; a radioprotection drug to treat people irradiated following a civil or military nuclear accident (NP02 NanoManganese); NanosiRNA COVID-19, an antiviral treatment solution for viral diseases; and NanosiRNA Resistant cancers and NanosiRNA Oncolytic virus for the treatment of oncology. The company was founded in 2003 and is based in Montpellier, France.
Company Valuation
Considering past and projected metrics, the stock is distinctly 'cheaper' than its peers. Specifically, the stock is 'cheap' on P/E, undervalued on EV/EBITDA, underpriced